People who quit taking popular GLP-1 drugs such as Ozempic might their jeopardize heart health, according to a new study.
In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results